异喹啉硫酸氢盐 | 5984-79-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 异喹啉硫酸氢盐
• 英文名称: isoquinoline; hydrogen sulfate
• 英文别名: isoquinoline; sulfate；Isochinolin; Hydrogensulfat；Isochinolin; Sulfat；hydron;isoquinolin-2-ium;sulfate
• CAS: 5984-79-2
• 化学式: C₉H₇N*H₂O₄S
• 分子量: 227.241
• InChiKey: PNVXLEZHGVTRFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.58
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  异喹啉硫酸氢盐 、 硫酸 以46%的产率得到
  参考文献：
  名称：

  REY, M.;VERGNANI, T.;DREIDING, A. S., HELV. CHIM. ACTA, 1985, 68, N 7, 1828-1834

  摘要：

  DOI：

文献信息

• [EN] REVERSIBLE NONDEPOLARIZING NEUROMUSCULAR BLOCKADE AGENTS AND METHODS FOR THEIR USE<br/>[FR] AGENTS DE BLOCAGE NEUROMUSCULAIRES NON DÉPOLARISANTS RÉVERSIBLES ET LEUR MÉTHODE
  申请人：UNIV CORNELL

  公开号：WO2010107488A1

  公开（公告）日：2010-09-23

  The invention provides neuromuscular blockade agents of the non-depolarizing type with few if any circulatory effects. Compounds of the invention include bis(isoquinolylalkanol) diesters of fumaric, maleic, succinic, and acetylenedicarboxylic acids; compositions suitable for parenteral administration of these compounds as a surgical adjunct to anesthesia, and methods of preparation of the compounds. Compounds of the invention can produce neuromuscular blockade of short or intermediate duration, which for various compounds can be reversed by administration of a thiol compound such as L-cysteine, D-cysteine or glutathione. For various compounds of the invention, the neuromuscular blockade effect can be reversed quickly, efficiently, and without notable side-effects.

  该发明提供了一种非去极化型神经肌肉阻滞剂，几乎没有任何循环效应。该发明的化合物包括富马酸、马来酸、琥珀酸和乙炔二羧酸的双(异喹啉基烷醇)二酯；适用于这些化合物作为手术辅助麻醉剂的静脉给药组合物，以及这些化合物的制备方法。该发明的化合物可以产生短暂或中等持续时间的神经肌肉阻滞，对于各种化合物，可以通过给予硫醇化合物如L-半胱氨酸、D-半胱氨酸或谷胱甘肽来逆转。对于该发明的各种化合物，神经肌肉阻滞效应可以迅速、高效地逆转，而且没有明显的副作用。
• REVERSIBLE NONDEPOLARIZING NEUROMUSCULAR BLOCKADE AGENTS AND METHODS FOR THEIR USE
  申请人：Savarese John J.

  公开号：US20120095041A1

  公开（公告）日：2012-04-19

  The invention provides neuromuscular blockade agents of the non-depolarizing type with few if any circulatory effects. Compounds of the invention include bis(isoquinolylalkanol) diesters of fumaric, maleic, succinic, and acetylenedicarboxylic acids; compositions suitable for parenteral administration of these compounds as a surgical adjunct to anesthesia, and methods of preparation of the compounds. Compounds of the invention can produce neuromuscular blockade of short or intermediate duration, which for various compounds can be reversed by administration of a thiol compound such as L-cysteine, D-cysteine or glutathione. For various compounds of the invention, the neuromuscular blockade effect can be reversed quickly, efficiently, and without notable side-effects.

  本发明提供了一种非去极化型的神经肌肉阻滞剂，其循环效应很少或没有。该发明的化合物包括富马酸、马来酸、琥珀酸和乙炔二羧酸的双(异喹啉基烷醇)二酯；适用于这些化合物的静脉注射制剂作为麻醉手术辅助剂，以及制备这些化合物的方法。该发明的化合物可以产生短期或中等期的神经肌肉阻滞效果，对于各种化合物，可以通过给予巯基化合物如L-半胱氨酸、D-半胱氨酸或谷胱甘肽来逆转。对于该发明的各种化合物，神经肌肉阻滞效果可以快速、有效地逆转，且没有明显的副作用。
• Process for production of decahydroisoquinoline
  申请人：NIPPON STEEL CHEMICAL CO., LTD.

  公开号：EP0185792A1

  公开（公告）日：1986-07-02

  A process for the production of decahydroisoquinoline is disclosed which comprises hydrogenating isoquinoline or partially hydrogenated isoquinoline in the presence of a ruthenium catalyst at a temperature of 110°C to 230°C under a hydrogen pressure of at least 10kg/cm2·G.

  本发明公开了一种生产十氢异喹啉的工艺，该工艺包括在钌催化剂存在下，在 110°C 至 230°C 的温度和至少 10kg/cm2-G 的氢气压力下，对异喹啉或部分氢化异喹啉进行氢化。
• 7-(γ-Diethylaminopropylamino)-isoquinoline¹
  作者：Richard A. Robinson

  DOI：10.1021/ja01200a030

  日期：1947.8
• COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS
  申请人：Liu Haiyan

  公开号：US20120004223A1

  公开（公告）日：2012-01-05

  The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.